SecBot SecBot
424B5 ·Filed Sep 8, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Impact 5/10
Horizondays Processed2mo ago SEC0001193125-26-384343
Notable filing: 424B5
Actionable Insight • Neutral

Monitor the final pricing supplement for coupon rates and total offering size, the key variable is how much Teva saves on interest versus the called notes. The refinancing is credit-neutral to mildly positive for bonds but does not change the equity thesis. Watch for any subsequent 8-K confirming the closing and redemption execution.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$36.76
T+0 close · Sep 8, 2026 · via day close
Latest settled
+6.45%
T+20 · $39.13 · next T+60 in 15d
Vs SPY
+4.73%
α at T+20
Latest observation
+27.37%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $36.76entry
  2. T+1 · 2mo ago +0.24%α +0.71% · $36.85
  3. T+5 · 2mo ago +6.77%α +7.89% · $39.25
  4. T+20 · 6w ago +6.45%α +4.73% · $39.13
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (2032-2037), with proceeds intended to fund the conditional redemption of up to ~$4.5B in higher-coupon notes (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This is a liability management refinancing that reduces near-term debt costs and extends maturities, but the offering size and final coupon rates are undisclosed in this preliminary filing. The transaction is credit-positive for bondholders (removing expensive debt) but neutral for equity holders as it does not change the fundamental business outlook or leverage trajectory beyond the refinancing math.

Key Facts

  • Teva is offering five series of senior unsecured notes: EUR 2033s, EUR 2036s, USD 2032s, USD 2034s, and USD 2037s.
  • Proceeds will fund conditional redemptions of up to $1.25B of 6.750% 2028 USD notes, $398M of 7.875% 2029 USD notes, €758M of 7.375% 2029 EUR notes, $450M of 4.750% 2027 USD notes, and €1.25B of 4.375% 2030 EUR notes.
  • The offering is conditioned on the redemptions, but the redemptions are not conditioned on the offering.
  • Teva had $16.65B of senior unsecured indebtedness outstanding as of June 30, 2026, and no secured debt.
  • LTM net revenues were $17.315B and LTM Adjusted EBITDA was $4.56B as of June 30, 2026.
  • The filing is preliminary, coupon rates, offering sizes, and final pricing are all placeholder values.
  • The underwriters include BNP Paribas, Citigroup, Goldman Sachs, J.P. Morgan, BofA, HSBC, Mizuho, and others.

Financial Impact

Refinancing of up to ~$4.5B in higher-coupon debt with new notes at current market yields; exact interest savings depend on final pricing, which is undisclosed.

interest expensedebt maturity profiletotal debt

Risk Factors

  • Offering size and coupon rates are undisclosed, actual terms may differ materially from market expectations.
  • The offering is not conditioned on the redemptions, creating execution risk if market conditions shift.
  • Teva's LTM net income attributable to Teva was only $706M, and the company reported a net loss of $207M in H1 2026, indicating thin earnings coverage of the enlarged debt base.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-384343
Document: 0001193125-26-384343-index-headers.html0001193125-26-384343
Document: 0001193125-26-384343-index.html0001193125-26-384343
Document: 0001193125-26-384343.txt0001193125-26-384343

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026